Antibiotic sensitivity pattern of clinical isolates of Proteus species with special reference to ESBL and Amp C production

M, Dr Suchitra Shenoy; Mohit, Mohit; Sinha, Richa

doi:10.15373/2249555x/mar2013/97

Cited by 5 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pandrug resistance was observed in 6 (3.4%) isolates which needs further testing by molecular methods to detect different resistance genes. Resistance to Imipenem was found in 16 isolates (9.3%) of which maximum cases were Proteus mirabilis i.e12 (75%).High antibiotic resistance was found among Proteus in other studies also (Reslinki et al, 2005;Rozalski et al, 2012;Sekowska et al, 2004;Shenoy et al, 2013).…”

Section: Resultsmentioning

confidence: 80%

Characterization of Proteus Species and Detection of Multi Drug Resistant (MDR) with Special Reference to ESBL Strains

Syntem¹,

Dutta²,

Kalyani³

2016

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 80%

Characterization of Proteus Species and Detection of Multi Drug Resistant (MDR) with Special Reference to ESBL Strains

Syntem¹,

Dutta²,

Kalyani³

2016

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

“…Similar observation has been reported by other studies whereas some studies have reported isolates more commonly from urine than other clinical specimens. [ 3 12 13 14 17 18 ]…”

Section: Discussionmentioning

confidence: 99%

“…[ 12 19 22 23 24 ] None of the isolates were resistant to piperacillin-tazobactam in our study and that of Tumbarello et al . [ 19 ] while Shenoy et al .,[ 3 ] Senthamarai et al .,[ 22 ] and Rudresh and Nagarathnamma[ 23 ] reported a low resistance of 4%–8%.…”

Section: Discussionmentioning

confidence: 99%

“…Our study revealed that 88.1% of Proteus species isolated from clinical specimens were β-lactamase producers while others have reported 60%–70%. [ 3 13 20 23 24 25 26 27 28 29 ] Pure AmpC producers were observed in 5.8% of isolates similar to Feglo and Opoku,[ 24 ] while Shenoy et al . [ 3 ] and Rudresh and Nagarathnamma[ 23 ] reported 11.9% and 15.1%, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Among the β-lactamases, the production of extended spectrum β-lactamases (ESBLs) and AmpC β-lactamases is most common. [ 3 ]…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Phenotypic detection and antibiogram of β-lactamase-producing proteus species in a tertiary care hospital, India

Hooja

Sharma

et al. 2016

Ann Med Health Sci Res

View full text Add to dashboard Cite

Background:Proteus species cause a variety of community- and hospital-acquired illnesses. Synthesis of β-lactamases is the predominant mechanism for resistance to β-lactam antibiotics. Among the β-lactamases, extended spectrum β-lactamases (ESBLs) and AmpC β-lactamases are the most common.Aim:The objective of this study was to determine the occurrence of ESBL and AmpC β-lactamases in Proteus species among various clinical isolates at a tertiary care hospital, India.Materials and Methods:This study was done to identify various species of Proteus from clinical samples (n = 3922). Antimicrobial susceptibility was performed by Kirby–Bauer disc diffusion method. ESBL production was detected by modified double-disc synergy test and indirect modified three-dimensional tests and AmpC β-lactamase production by AmpC disc test and modified Hodge test.Results:Proteus species were isolated in 5.4% (101/1876) specimens. Three Proteus species isolated were Proteus mirabilis 62.4% (63/101), Proteus vulgaris 29.7% (30/101), and Proteus penneri 7.9% (8/101). ESBL producers confirmed by both tests were of 88.1% (89/101). Only AmpC β-lactamase was produced by four isolates. Coproduction of ESBL and AmpC β-lactamase was observed in 58.4% (52/89) of isolates. Twelve isolates were non-β-lactamase producers. Multidrug resistance (MDR) was found in 95.1% (96/101) of isolates, 50.5% (51/101) were possibly extensively drug resistant and none were pan drug resistant. None of the isolates were resistant to piperacillin-tazobactam. P. penneri isolates exhibited high resistance to most of the antibiotics.Conclusions:A high prevalence of ESBL and AmpC β-lactamases was found that concurrently showed MDR. Phenotypic methods for the detection of β-lactamases are easy and simple and can be implemented in routine diagnostic laboratories along with susceptibility testing. These data will assist the clinicians in the management and control of infections.

show abstract

Prevalence of extended-spectrum β-lactamases, AmpC, and carbapenemases in Proteus mirabilis clinical isolates

2022

View full text Add to dashboard Cite

Background Proteus mirabilis is an opportunistic pathogen, causing a variety of community-acquired and nosocomial illnesses. It poses a potential threat to patients via the production of β-lactamases, which decrease the efficacy of antimicrobial treatment and impair the management of its pathogenicity. Hence, this study was established to determine the prevalence of extended-spectrum β-lactamases (ESBLs), AmpC, and carbapenemases of P. mirabilis isolated from various clinical specimens. Results Proteus mirabilis was identified in 20.7% (58/280) of specimens. ESBL producers were present at a rate of 51.7% (30/58). All AmpC-positive isolates (n = 20) produced ESBLs as well, so 66.7% of ESBL-producing isolates coproduced AmpC enzymes. The modified Hodge test confirmed carbapenemase production in six out of seven imipenem nonsusceptible isolates. Of these, only two (5.7%) isolates were also ESBL-and AmpC-positive. Antibiotic resistance reached the highest level for cotrimoxazole (62.1%, n = 36/58 isolates) and the lowest for imipenem (12.1%, n = 7/58 isolates). The levels of multidrug-resistant (MDR) was 41.4% among the tested isolates. The blaSHV (83.3%), blaAmpC (80%), and blaVIM-1 (50%) were the most detected genes in phenotypically confirmed ESBL-, AmpC-, and carbapenemase-producing isolates, respectively. Besides, more than a half of the tested P. mirabilis strains (53%) coproduced ESBLs and AmpC. Moreover, two isolates coproduced ESBLs and AmpC together with carbapenemases. Furthermore, dendrogram analysis showed great genetic divergence based on the 21 different enterobacterial repetitive intergenic consensus (ERIC) patterns (P1–P21) through the 34 β-lactamase producers. ERIC analysis distinguished clonal similarities between isolates 21 and 22 in P2 and 9 and 10 in P4, which were isolated from the same clinical source and possessed similar patterns of β-lactamase-encoding genes. Conclusion Hence, there is an urgent need to monitor hospitalized patients and improve healthcare in order to reduce the incidence of infection and outbreaks of infection with antibiotic-resistant Proteus.

show abstract

Antibiotic sensitivity pattern of clinical isolates of Proteus species with special reference to ESBL and Amp C production

Cited by 5 publications

References 5 publications

Characterization of Proteus Species and Detection of Multi Drug Resistant (MDR) with Special Reference to ESBL Strains

Characterization of Proteus Species and Detection of Multi Drug Resistant (MDR) with Special Reference to ESBL Strains

Phenotypic detection and antibiogram of β-lactamase-producing proteus species in a tertiary care hospital, India

Prevalence of extended-spectrum β-lactamases, AmpC, and carbapenemases in Proteus mirabilis clinical isolates

Contact Info

Product

Resources

About